Avenue Therapeutics Receives Complete Response Letter from the FDA for IV Tramadol
12 oct. 2020 06h30 HE
|
Avenue Therapeutics
NEW YORK, Oct. 12, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today...
Avenue Therapeutics Announces Publication of a Review of IV Tramadol
09 sept. 2020 08h00 HE
|
Avenue Therapeutics
NEW YORK, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today...
Avenue Therapeutics Reports Second Quarter 2020 Financial Results and Recent Corporate Highlights
14 août 2020 07h30 HE
|
Avenue Therapeutics
NEW YORK, Aug. 14, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today...
Avenue Therapeutics Announces Publication of Phase 3 Bunionectomy Study Results
21 juil. 2020 08h30 HE
|
Avenue Therapeutics
NEW YORK, July 21, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today...
Avenue Therapeutics Announces Publications in Peer-Reviewed Journals
05 juin 2020 08h30 HE
|
Avenue Therapeutics
NEW YORK, June 05, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today...
Avenue Therapeutics to Host Virtual Annual Meeting of Stockholders
29 mai 2020 08h30 HE
|
Avenue Therapeutics
NEW YORK, May 29, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today...
Avenue Therapeutics Reports First Quarter 2020 Financial Results and Recent Corporate Highlights
11 mai 2020 07h30 HE
|
Avenue Therapeutics
NEW YORK, May 11, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today...
Avenue Therapeutics Announces Presentation of IV Tramadol E-Posters
23 avr. 2020 08h30 HE
|
Avenue Therapeutics
NEW YORK, April 23, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today...
Avenue Therapeutics Reports Full Year 2019 Financial Results and Recent Corporate Highlights
30 mars 2020 07h30 HE
|
Avenue Therapeutics
NEW YORK, March 30, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today...
Avenue Therapeutics Announces New Drug Application for IV Tramadol Accepted for Review by FDA
13 févr. 2020 08h00 HE
|
Avenue Therapeutics
NEW YORK, Feb. 13, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today...